Lonza and Australian Firm Establish Manufacturing Alliance

Lonza says it has entered into a strategic alliance with Mesoblast (Melbourne, Australia), a developer of innovative biological products for regenerative medicine, for clinical and long-term commercial production of Mesoblast’s off-the-shelf allogeneic adult stem cell products. The alliance will provide Mesoblast with certainty of capacity to meet long-term global supply of its proprietary mesenchymal precursor cell (MPC) products. “The cell therapy market is anticipated to become a major growth industry with the potential to mirror the growth we have...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers